Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy

被引:29
|
作者
Ko, Na Re [1 ,2 ]
Van, Se Young [1 ,2 ]
Hong, Sung Hwa [3 ]
Kim, Seog-Young [4 ]
Kim, Miran [2 ]
Lee, Jae Seo [5 ]
Lee, Sang Ju [2 ]
Lee, Yong-kyu [6 ]
Kwon, Il Keun [5 ]
Oh, Seung Jun [2 ]
机构
[1] Asan Inst Life Sci, Biomed Res Ctr, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Nucl Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[3] Univ Toronto, Dept Chem Engn & Appl Chem, 200 Coll St, Toronto, ON M5S 3E5, Canada
[4] Univ Ulsan, Coll Med, Dept Convergence Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[5] Kyung Hee Univ, Sch Dent, Dept Dent Mat, 26 Kyungheedae Ro, Seoul 02447, South Korea
[6] Korea Natl Univ Transportat, Dept Chem & Biol Engn, 50 Daehak Ro, Cheongju, South Korea
基金
新加坡国家研究基金会;
关键词
stimuli-responsive degradation system; glutathione; breast cancer; Herceptin; active targeting; PEGylation; IN-VITRO; NONCOVALENT PEGYLATION; 1ST-LINE TREATMENT; PHASE-II; TRASTUZUMAB; OXIDE; CHEMOTHERAPY; DELIVERY; GLUTATHIONE; NANOMATERIALS;
D O I
10.3390/nano10010091
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Dual stimuli-responsive degradable carbon-based nanoparticles (DS-CNPs) conjugated with Herceptin (HER) and polyethylene glycol (PEG) have been designed for the treatment of HER2-positive breast cancer. Each component has been linked through disulfide linkages that are sensitive to glutathione in a cancer microenvironment. beta-cyclodextrin (beta-CD) on the surface of DS-CNPs formed an inclusion complex (DL-CNPs) with doxorubicin (DOX) at a high loading capacity of 5.3 +/- 0.4%. In response to a high level of glutathione (GSH) and low pH in a tumor environment, DL-CNPs were rapidly degraded and released DOX in a controlled manner via disruption of host-guest inclusion. These novel DL-CNPs exhibited high cellular uptake with low toxicity, which induced the efficient inhibition of antitumor activity both in vitro and in vivo. Cell viability, confocal laser scanning microscopy, and animal studies indicate that DL-CNPs are a great platform with a synergistically enhanced antitumor effect from the dual delivery of HER and DOX in DL-CNPs.
引用
收藏
页数:15
相关论文
共 50 条
  • [11] Quantum Dot-Based Immunofluorescent Imaging of Ki67 and Identification of Prognostic Value in HER2-Positive (Non-Luminal) Breast Cancer(vol 18, pgno 207, 2023)
    Sun, J.
    Chen, C.
    Jiang, G.
    Tian, W.
    Li, Y.
    Sun, S.
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2023, 18 : 207 - 207
  • [12] Investigation of the genomic evolution of HER2-positive breast cancer following progression on dual HER2-targetted therapy with Trastuzumab and Tucatinib
    Blackley, Elizabeth
    van Geelen, Courtney
    Ko, Yi-An
    Wong, Stephen
    Yeung, Miriam
    Luen, Stephen
    Dawson, Sarah-Jane
    Loi, Sherene
    CANCER RESEARCH, 2024, 84 (09)
  • [13] Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia
    Xu, Binghe
    Kim, Sung-Bae
    Inoue, Kenichi
    Lee, JuRueyJiuan
    Zhang, Bo
    Bryce, Richard
    Chow, Louis W-C
    FUTURE ONCOLOGY, 2019, 15 (28) : 3243 - 3253
  • [14] Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients
    Zhao, Feng
    Zhang, Hongzhen
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 845 - 853
  • [15] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    Atallah, N. M.
    Alsaleem, M.
    Toss, M. S.
    Mongan, N. P.
    Rakha, E.
    BRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1692 - 1705
  • [16] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    N. M. Atallah
    M. Alsaleem
    M. S. Toss
    N. P. Mongan
    E. Rakha
    British Journal of Cancer, 2023, 129 : 1692 - 1705
  • [17] Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC)
    Reynolds, Kerry Lynn
    Bhatia, Ashmeet
    Cheng, XingXing
    Smith, Barbara Lynn
    Specht, Michelle Connolly
    Moy, Beverly
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [18] Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with HER2 Loss After Dual-Target Adjuvant Therapy: A Case Report
    Ouyang, Wei
    Liu, Yixin
    Cao, Jun
    Chen, Jinghua
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (02) : e172 - e176
  • [19] Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
    Krizic, Marija
    Popovic, Marina
    Silovski, Tajana
    Grbin, Dorotea
    Plavetic, Natalija Dedic
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) : 413 - 423
  • [20] Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab
    Shu, Mengjun
    Gao, Feng
    Yu, Chulang
    Zeng, Min
    He, Guili
    Wu, Yan
    Su, Yanjie
    Hu, Nantao
    Zhou, Zhihua
    Yang, Zhi
    Xu, Lin
    NANOTECHNOLOGY, 2020, 31 (33)